ComplianceOnline

FDA: Boxed Warning on Plavix

  • Date: March 14, 2010
  • Source: admin
Webinar All Access Pass Subscription Abstract:

FDA has announced new boxed warning on Plavix. Plavix, which is an anti-blood clotting drug, can prove to be less effective in people who cannot digest the drug to convert it to its active form.

Plavix is one of the most effective medicines in terms of alleviating the risk of heart attack, unstable angina, cardiovascular death, and stroke in patients by making platelets less likely to form blood clots. Nevertheless, for its proper functioning, Plavix needs to be metabolized into its active form by the liver enzyme, CYP2C19.

Bookmark and Share

Trending Compliance Trainings

Challenges of an Effective Change Control Program
By - Kenneth Christie
On Demand Access Anytime
Implementation and Management of GMP Data Integrity
By - Danielle DeLucy
On Demand Access Anytime
FDA Compliance and Clinical Trial Computer System Validation
By - Carolyn Troiano
On Demand Access Anytime
Biocompatibility Testing; what you need to know
By - Mike Colvin
On Demand Access Anytime
Best Sellers
You Recently Viewed
    Loading